Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. | Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease ...

Solventum estimates that Acera will likely post about $90 million in sales for 2025. The deal is expected to be "slightly dilutive" to adjusted earnings per share in 2026 and accretive to adjusted ...

The November storm clouds may have parted above the Jefferies Global Healthcare Conference in London last week, but market ...

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past ...

Roche has claimed the exclusive international rights to Freenome’s multiomic cancer screening approaches, toward the goal of ...

The FDA says it is hiring more than 1,000 new employees and rolling out a pilot communication program in efforts to speed up ...

The CDC is instructing scientists to end all research involving monkeys by the end of the year, in a move that will ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while ...

The survey was disseminated among biopharma CEOs and regulatory affairs leaders and focused on recent experiences with the ...

Nurix Therapeutics is trimming its workforce not long after launching a pivotal phase 2 trial for its lead cancer asset. | ...

GE HealthCare plans to pay $2.3 billion in cash to acquire imaging software developer Intelerad, toward the goal of building ...

After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience ...